BDX Becton Dickinson
Durable hospital consumables franchise priced near fair value; upside needs GAAP margins actually catching adjusted ones.
The story
Becton Dickinson is a scaled medical-technology franchise in syringes, needles, IV catheters, infusion pumps (Alaris), and medication management. It has razor/razor-blade consumable lock-in with hospitals. After separating Biosciences & Diagnostics into the Waters transaction, it is a mature, mid-single-digit grower. Reported GAAP margins are depressed by heavy acquisition amortization, restructuring, and quality remediation, which masks underlying adjusted margins in the low-to-mid 20s.
Growth stays at roughly 3-5%, matching BD's mature consumables mix and modest portfolio shrink from the separation. The margin target of 19% sits between the depressed 11-12% GAAP figure and the ~25% adjusted figure: it treats part of the amortization and the recurring restructuring as real economic costs. The reported 0.47 sales-to-capital is inflated by goodwill, so I use 1.0 as the incremental figure because organic reinvestment is far lighter. Beta of 0.85 reflects defensive hospital demand, partly offset by $18.5B of net debt.
Value drivers
| Revenue growth (Y1) | 3.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 7y |
| Target operating margin | 19.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.00 |
| Beta | 0.85 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.4% |
| Terminal WACC | 9.9% |
Valuation bridge
| PV of explicit FCFF | 13.25B |
| PV of terminal value | 24.25B |
| Equity value | 18.58B |
| ÷ shares → per share | $68.21 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 21.47B | 3.0% | 11.8% | 2.26B | 625.20M | 1.64B | 1.49B |
| 2 | 22.11B | 3.0% | 13.6% | 2.68B | 643.96M | 2.04B | 1.70B |
| 3 | 22.77B | 3.0% | 15.4% | 3.13B | 663.27M | 2.47B | 1.88B |
| 4 | 23.46B | 3.0% | 17.2% | 3.60B | 683.17M | 2.92B | 2.04B |
| 5 | 24.16B | 3.0% | 19.0% | 4.09B | 703.67M | 3.39B | 2.17B |
| 6 | 24.88B | 3.0% | 19.0% | 4.22B | 724.78M | 3.49B | 2.04B |
| 7 | 25.63B | 3.0% | 19.0% | 4.34B | 746.52M | 3.60B | 1.92B |
Key risks
- Alaris pump and other quality/FDA remediation issues recur, delaying margin recovery
- China volume-based procurement and US hospital capex pressure weigh on pricing and volumes
- High leverage after the separation limits flexibility if integration or restructuring costs keep recurring
Catalysts
- Clean execution post-Waters separation with debt paydown and a simplified, higher-margin RemainCo
- GAAP margins converging toward adjusted levels as amortization rolls off and restructuring ends